



Post Authorisation Assessments

Ridaflea (Imidacloprid) 100 mg Spot-on Solution for Medium Dogs Vm 39787/4082

•	13 April 2024	Unlimited renewal.
•	26 January 2024	Change to the name a manufacturer of the finished product.
•	02 December 2022	New certificate of suitability from an already approved manufacturer.
•	14 August 2019	Change of specification(s) of a former non Pharmacopoeial active substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State.